Eli Lilly experienced an 11% share price increase over the past month, largely influenced by the affirmation of a $1.50 per share dividend declared for the second quarter. The announcement of Q1 earnings, showing significant revenue growth to $12,729 million, and promising results from the SURPASS-3 trial for tirzepatide, contributed to investor optimism. Despite the broader market's marginal fluctuations amid concerns over tariffs and Fed decisions, Eli Lilly's strong earnings guidance and product development announcements provided a counterbalance, driving the stock's notable outperformance compared to the broader market's 2% rise. Eli Lilly has 2 weaknesses (and 1 which shouldn't be ignored) we think you should know about.NYSE:LLY Earnings Per Share Growth as at May 2025 AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The recent news surrounding Eli Lilly, including the affirmation of a $1.50 per share dividend and the promising outcomes from the SURPASS-3 trial, has boosted short-term investor sentiment. This optimism aligns well with the company's narrative of manufacturing expansion and strategic partnerships, such as the one with OpenAI, which are poised to bolster future revenue opportunities. The company's robust five-year total shareholder return, which surged by a very large percentage, showcases its impressive long-term performance. Over the past year, however, Eli Lilly's shares underperformed the US market's return of 8.2% but outpaced the US Pharmaceuticals industry's 3.4% decline. Increased manufacturing capabilities and successful trial results support the positive revenue and earnings growth forecasts. These developments may fuel Eli Lilly's projected annual revenue growth of 22.7% and possibly improve its profit margins despite potential challenges like pricing pressures and rising R&D costs. With a current share price of US$885.20 and a consensus analyst price target of approximately US$991.97, the stock has room to potentially close the 10.8% gap, reflecting broader analyst expectations. This positive sentiment suggests confidence in the firm's long-term growth prospects, despite short-term market variabilities. Evaluate Eli Lilly's historical performance by accessing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NYSE:LLY. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Eli Lilly (NYSE:LLY) Declares US$1.50 Second Quarter Dividend For 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...